| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 7.855 | 531 | 3.771 | 5.660 | 13.666 | 13.004 | 13.971 |
| Total Income - EUR | - | - | 0 | 7.855 | 531 | 3.771 | 5.660 | 13.666 | 13.004 | 13.971 |
| Total Expenses - EUR | - | - | 0 | 2.008 | 846 | 1.120 | 2.026 | 974 | 3.413 | 1.556 |
| Gross Profit/Loss - EUR | - | - | 0 | 5.848 | -315 | 2.651 | 3.634 | 12.692 | 9.591 | 12.415 |
| Net Profit/Loss - EUR | - | - | 0 | 5.612 | -331 | 2.546 | 3.464 | 12.282 | 8.240 | 10.691 |
| Employees | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Tanydav Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | 0 | 6.551 | 6.882 | 17.036 | 21.027 | 34.582 | 21.844 | 31.981 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 14.151 | 24.693 |
| Cash | - | - | 0 | 6.551 | 6.882 | 17.036 | 21.027 | 34.582 | 7.692 | 7.288 |
| Shareholders Funds | - | - | 0 | 5.621 | 5.191 | 14.411 | 17.555 | 12.290 | 20.493 | 31.069 |
| Social Capital | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debts | - | - | 0 | 931 | 1.690 | 2.625 | 3.472 | 22.292 | 1.350 | 912 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Tanydav Med Srl